Studies with Benzodiazepines Lorazepam — Under steady-state conditions for duloxetine (60 mg
91) and diastolic blood pressure
Duloxetine enhances 5-HT and NE function in the central nervous system and is an effective treatment for major depressive disorder (MDD), pain, and stress urinary
Other
5-fold, and duloxetine t 1/2 was increased approximately 3-fold
53 duloxetine, but delays the time to reach peak concentration from 6 to 10 hours and it marginally 54 decreases the extent of absorption (AUC) by about 10%
The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its active 5 Interaction studies show that CYP1A2 inhibition increases duloxetine exposure to a clinically significant degree (AUC 0-t increased by 460% in the presence of fluvoxamine), 8 whereas the exposure of duloxetine in the presence of CYP2D6 inhibitors or in CYP2D6 poor metabolizers is increased to a lesser extent (paroxetine, a potent
Duloxetine increased the AUC (tau,ss) of tolterodine by 71% [geometric mean, 95% confidence interval (CI) 31, 123], and its C (max,ss) by 64% (CI 30, 106), and prolonged its t (1/2) by 14% (CI 1, 28)
Duloxetine treatment along with Metoprolol results in 3
5-fold, and duloxetine t 1/2 was increased approximately 3-fold
Serum duloxetine C max and AUC increased linearly after administration
Linear PK properties were found at doses of 30 to 90 mg
Because of this effect, certain other drugs including other TCAs More precisely, in a clinical study that included healthy volunteers, duloxetine was responsible for a 1
ResultsAt steady state on Day 19, duloxetine's AUC and Cmax were increased 540% and 471